Evidence map›Paper›PMID 35949328›Full record

ArticleExperimental and therapeutic medicine2022

IL-6 inhibitors effectively reverse post-infarction cardiac injury and ischemic myocardial remodeling via the TGF-β1/Smad3 signaling pathway.

Jiahong Wang, Minghong Wang, Xiancheng Lu, Yi Zhang, Siliang Zeng, Xin Pan, Yimeng Zhou, Hui Wang, Nannan Chen, Fengfeng Cai and 1 more

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Experimental and therapeutic medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed, 1 pooled it
2.8field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 1 synthesis or guideline pooled it, 18 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Review
  4. Article
  5. Article
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Article
  12. Article
  13. Article
  14. Review
  15. Review
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 1 country.

Jiahong WangDepartment of Cardiology, Yangpu Hospital, School of Medicine, Tongji University, Shanghai 200090, P.R. China.
Minghong WangDepartment of Health Management Center, Shanghai Public Health Clinical Center, Shanghai 201508, P.R. China.
Xiancheng LuDepartment of Nutrition, Shanghai Yangpu Hospital of Traditional Chinese Medicine, Shanghai 200090, P.R. China.
Yi ZhangDepartment of Breast Surgery, Yangpu Hospital, School of Medicine, Tongji University, Shanghai 200090, P.R. China.
Siliang ZengDepartment of Rehabilitation Therapy, Shanghai Normal University Tianhua College, Shanghai 201815, P.R. China.
Xin PanInstitute for Regenerative Medicine, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai 200123, P.R. China.
Yimeng ZhouDepartment of Cardiology, Yangpu Hospital, School of Medicine, Tongji University, Shanghai 200090, P.R. China.
Hui WangLaboratory of Tumor Molecular Biology, School of Basic Medical Sciences, Shanghai University of Medicine and Health Sciences, Shanghai 201318, P.R. China.
Nannan ChenDepartment of Cardiology, Yangpu Hospital, School of Medicine, Tongji University, Shanghai 200090, P.R. China.
Fengfeng CaiDepartment of Breast Surgery, Yangpu Hospital, School of Medicine, Tongji University, Shanghai 200090, P.R. China.
Ewelina BiskupLaboratory of Tumor Molecular Biology, School of Basic Medical Sciences, Shanghai University of Medicine and Health Sciences, Shanghai 201318, P.R. China.
Yangpu Hospital of Tongji University · CNShanghai University of Medicine and Health Sciences · CNShanghai East Hospital · CNShanghai Normal University · CNShanghai Public Health Clinical Center · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Approximately one in four myocardial infarctions occur in older patients. The majority of therapeutic advances are either not appropriate or not tested in elderly patients. The main reasons for deviating from the guidelines are justified concerns regarding the effectiveness of the recommended forms of therapy, fear of adverse drug reactions and ethical concerns. Targeting interleukin 6 (IL-6) for ventricular remodeling after cardiovascular damage is a feasible alternative to standard polypharmaceutics, but the underlying molecular mechanisms are not well understood. Continuous activation of the IL-6-associated cytokine receptor gp130 leads to cardiomyopathic hypertrophy. TGFβ1 is involved in forming fibrosis in various organs, and its overexpression can cause myocardial hypertrophy and fibrosis. Il-6 has been hypothesized to be indirectly involved in cardiac remodeling via the TGFβ1/Smad signaling transduction pathway. In the present study, a rat model of acute myocardial ischemia, IL-6 and IL-6 receptor blockers were injected directly into the necrotic myocardium. Changes in cardiac function, myocardial infarction area, myocardial collagen, necrotic myocardial fibrosis and levels of TGFβ1, IL-6 and MMP2/9 were quantified in myocardial tissue fibrosis by ELISA. The present study demonstrated that IL-6 stimulated myocardial fibrosis through the TGFβ1-Smad-MM2/9 signaling transduction pathway. Overall, this provided a solid foundation for understanding the relationship between IL-6 and ventricular remodeling.

Indexed as

interleukin 6interleukin 6 inhibitormyocardial infarctionrejuvenationTGFβ1/Smad3ventricular remodeling

Identifiers

PMID35949328
PMCPMC9353402
OpenAlexW4285726748

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.